Evidence map›Paper›PMID 39034726›Full record

ArticleCardiovascular & hematological disorders drug targets2024

Diltiazem Hydrochloride Floating Matrix Tablet: Formulation and

Krishna D Koradia, Bhavin K Jotaniya, Hiral D Koradia

Abstract read
PubMed Publisher
In one paragraph

Article in Cardiovascular & hematological disorders drug targets, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Krishna D KoradiaSchool of Pharmacy, Indrashil University, Rajpur, Kadi, Mehsana, Gujarat, 382715, India.ORCID 0009-0007-2849-9746
Bhavin K JotaniyaDepartment of Pharmaceutical Sciences, Saurashtra University, Rajkot, Gujarat, 360005, India.
Hiral D KoradiaDepartment of Pharmaceutics, L. M. College of Pharmacy, Ahmedabad, Gujarat, 380009, India.ORCID 0000-0002-3841-735X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDiltiazem hydrochloride is a calcium channel-blocker with a plasma elimination half-life of 4.4 ± 1.3 h and has a narrow absorption window. So, this work aimed to prepare a gastro-retentive floating matrix tablet.

methodsThe direct compression method was used to manufacture tablets. 3

resultsThe high amount of HPMC K100M and sodium bicarbonate shows good results. The optimized preparation was evaluated for differential scanning calorimetry,

conclusionFrom this study, it can be concluded that the gastro-retentive diltiazem hydrochloride floating matrix tablet was successfully prepared and retained inside the rabbit stomach for up to 6 h and was stable under accelerated stability study.

Indexed as

DiltiazemTabletsAnimalsCalcium Channel BlockersChemistry, PharmaceuticalDelayed-Action PreparationsDrug StabilityHypromellose DerivativesMaleRabbitsSodium BicarbonateCalcium Channel BlockersDelayed-Action PreparationsDiltiazemHypromellose DerivativesSodium BicarbonateTabletsabdominal X-ray imagingdiltiazem hydrochloridefactorial designgastro-retentive matrix floating tablethydroxypropyl methylcellulose (HPMC) K100M.Psyllium husk

Identifiers

PMID39034726

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.